Managing menopausal symptoms after breast cancer – A multidisciplinary approach

  • Paul A. Cohen
    Corresponding author at: St. John of God Hospital, Bendat Family Comprehensive Cancer Centre, 12 Salvado Road, Subiaco, Western Australia, Australia.
    St. John of God Hospital Bendat Family Comprehensive Cancer Centre, 12 Salvado Road, Subiaco, Western Australia 6008, Australia

    School of Women's and Infants’ Health, University of Western Australia, 35 Stirling Highway, Crawley, Western Australia 6009, Australia

    Institute for Health Research, University of Notre Dame Australia, 32 Mouat Street Fremantle, Western Australia 6160, Australia
    Search for articles by this author
  • Annabelle Brennan
    Department of Obstetrics and Gynecology, Royal Women's Hospital, 20 Flemington Road, Parkville, Victoria 3052, Australia
    Search for articles by this author
  • Jennifer L. Marino
    Department of Obstetrics and Gynecology, The University of Melbourne, Parkville, Victoria 3052, Australia

    Department of Obstetrics and Gynecology, Royal Women's Hospital, 20 Flemington Road, Parkville, Victoria 3052, Australia
    Search for articles by this author
  • Christobel M. Saunders
    Division of Surgery, School of Medicine, University of Western Australia, Crawley, Western Australia, Australia
    Search for articles by this author
  • Martha Hickey
    Department of Obstetrics and Gynecology, The University of Melbourne, Parkville, Victoria 3052, Australia

    Department of Obstetrics and Gynecology, Royal Women's Hospital, 20 Flemington Road, Parkville, Victoria 3052, Australia
    Search for articles by this author


      • Menopausal symptoms after breast cancer are common and may be severe.
      • Menopausal symptoms may lead to decreased compliance with adjuvant hormonal therapy.
      • Multidisciplinary care is associated with improved outcomes after breast cancer.


      More than 6 million women worldwide are living with a past diagnosis of breast cancer. Most survive their illness, and management of the long-term consequences of treatment has become a priority in cancer care. Menopausal symptoms affect most breast cancer survivors and may significantly impair quality of life. We describe a multidisciplinary model to evaluate and manage these women using a patient-focused approach. The ‘Multidisciplinary Menopause After Cancer Clinic’ includes gynecologists, endocrinologists, GPs, a psychologist and a clinical nurse specialist. Benefits of this model include improved coordination of patient care, education, communication and evidence-based decision making.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • Eser S.
        • Mathers C.
        • Rebelo M.
        • et al.
        Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
        Int. J. Cancer. 2015; 136: E359-E386
        • Carpenter J.S.
        • Rand K.L.
        Modeling the hot flash experience in breast cancer survivors.
        Menopause. 2008; 15: 469-475
        • Holmberg L.
        • Iversen O.E.
        • Rudenstam C.M.
        • Hammar M.
        • Kumpulainen E.
        • Jaskiewicz J.
        • et al.
        Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
        J. Natl. Cancer Inst. 2008; 100: 475-482
        • Meggetto O.
        • Maunsell E.
        • Chlebowski R.
        • Goss P.
        • Tu D.
        • Richardson H.
        Factors associated with early discontinuation of study treatment in the mammary prevention. 3 Breast cancer chemoprevention trial.
        J. Clin. Oncol. 2017; 35: 629-635
        • Goodwin P.J.
        • Ennis M.
        • Pritchard K.I.
        • Trudeau M.
        • Hood N.
        Risk of menopause during the first year after breast cancer diagnosis.
        J. Clin. Oncol. 1999; 17: 2365-2370
        • Schover L.R.
        Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility.
        J. Clin. Oncol. 2008; 26: 753-758
        • Cancer Australia
        Management of Menopausal Symptoms in Women With a History of Breast Cancer.
        2016 (URL: (accessed 03.03.17))
        • EBCTCG
        Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
        Lancet. 2015; 386: 1341-1352
        • Maas A.H.
        • Ottevanger N.
        • Atsma F.
        • Cramer M.J.
        • Leiner T.
        • Poortmans P.
        Cardiovascular surveillance in breast cancer treatment: a more individualized approach is needed.
        Maturitas. 2016; 89: 58-62
        • Abdel-Qadir H.
        • Austin P.C.
        • Lee D.S.
        • Amir E.
        • Tu J.V.
        • Thavendiranathan P.
        • et al.
        A population-based study of cardiovascular mortality following early-stage breast cancer.
        JAMA Cardiol. 2017; 2: 88-93
        • van Westerop L.L.
        • Arts-de Jong M.
        • Hoogerbrugge N.
        • de Hullu J.A.
        • Maas A.H.
        Cardiovascular risk of BRCA1/2 mutation carriers: a review.
        Maturitas. 2016; 91: 135-139
        • Pesek MO S.S.
        • Fogarty A.
        • Stuckey C.
        • Raker M.
        • Clark E.
        • Kunkel J.G.
        Sexual function after breast cancer surgery.
        Abstr. Gynecol. Oncol. 2015; 139: 588
        • Maass S.W.
        • Roorda C.
        • Berendsen A.J.
        • Verhaak P.F.
        • de Bock G.H.
        The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: a systematic review.
        Maturitas. 2015; 82: 100-108
        • Ramalho M.
        • Fontes F.
        • Ruano L.
        • Pereira S.
        • Lunet N.
        Cognitive impairment in the first year after breast cancer diagnosis: a prospective cohort study.
        Breast (Edinb. Scotl.). 2017; 32: 173-178
        • Jim H.S.
        • Phillips K.M.
        • Chait S.
        • Faul L.A.
        • Popa M.A.
        • Lee Y.H.
        • et al.
        Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.
        J. Clin. Oncol. 2012; 30: 3578-3587
        • Amidi A.
        • Christensen S.
        • Mehlsen M.
        • Jensen A.B.
        • Pedersen A.D.
        • Zachariae R.
        Long-term subjective cognitive functioning following adjuvant systemic treatment: 7–9 years follow-up of a nationwide cohort of women treated for primary breast cancer.
        Br. J. Cancer. 2015; 113: 794-801
        • Menning S.
        • de Ruiter M.B.
        • Veltman D.J.
        • Boogerd W.
        • Oldenburg H.S.
        • Reneman L.
        • et al.
        Changes in brain white matter integrity after systemic treatment for breast cancer: a prospective longitudinal study.
        Brain Imaging Behav. 2017;
        • Treanor C.J.
        • McMenamin U.C.
        • O’Neill R.F.
        • Cardwell C.R.
        • Clarke M.J.
        • Cantwell M.
        • et al.
        Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment.
        Cochrane Database Syst. Rev. 2016; : Cd011325
        • Savard J.
        • Morin C.M.
        Insomnia in the context of cancer: a review of a neglected problem.
        J. Clin. Oncol. 2001; 19: 895-908
        • Fiorentino L.
        • Ancoli-Israel S.
        Insomnia and its treatment in women with breast cancer.
        Sleep Med. Rev. 2006; 10: 419-429
        • Accortt E.E.
        • Bower J.E.
        • Stanton A.L.
        • Ganz P.A.
        Depression and vasomotor symptoms in young breast cancer survivors: the mediating role of sleep disturbance.
        Arch. Women's Ment. Health. 2015; 18: 565-568
        • Caron M.
        • Durand M.J.
        • Tremblay D.
        Perceptions of breast cancer survivors on the supporting practices of their supervisors in the return-to-work process: a qualitative descriptive study.
        J. Occup. Rehabil. 2017;
        • Islam T.
        • Dahlui M.
        • Majid H.A.
        • Nahar A.M.
        • Mohd Taib N.A.
        • Su T.T.
        • et al.
        Factors associated with return to work of breast cancer survivors: a systematic review.
        BMC Public Health. 2014; 14: S8
        • Bilodeau K.
        • Tremblay D.
        • Durand M.J.
        Exploration of return-to-work interventions for breast cancer patients: a scoping review.
        Support. Care Cancer. 2017;
        • Hickey M.
        • Emery L.I.
        • Gregson J.
        • Doherty D.A.
        • Saunders C.M.
        The multidisciplinary management of menopausal symptoms after breast cancer: a unique model of care.
        Menopause. 2010; 17: 727-733
        • Fleissig A.
        • Jenkins V.
        • Catt S.
        • Fallowfield L.
        Multidisciplinary teams in cancer care: are they effective in the UK?.
        Lancet Oncol. 2006; 7: 935-943
        • Taylor C.
        • Shewbridge A.
        • Harris J.
        • Green J.S.
        Benefits of multidisciplinary teamwork in the management of breast cancer.
        Breast Cancer (Dove Med Press). 2013; 5: 79-85
        • Fahlen M.
        • Fornander T.
        • Johansson H.
        • Johansson U.
        • Rutqvist L.E.
        • Wilking N.
        • et al.
        Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.
        Eur. J. Cancer. 2013; 49: 52-59
        • Kenemans P.
        • Bundred N.J.
        • Foidart J.M.
        • Kubista E.
        • von Schoultz B.
        • Sismondi P.
        • et al.
        Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
        Lancet Oncol. 2009; 10: 135-146
        • Hickey M.
        • Marino J.L.
        • Braat S.
        • Wong S.
        A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.
        Breast Cancer Res. Treat. 2016; 158: 79-90
        • Barton D.L.
        • Wender D.B.
        • Sloan J.A.
        • Dalton R.J.
        • Balcueva E.P.
        • Atherton P.J.
        • et al.
        Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.
        J. Natl. Cancer Inst. 2007; 99: 672-679
      1. Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment.
        2017 ( Identifier: NCT01573442. (accessed 06.04.17))
        • Marino J.L.
        • Saunders C.M.
        • Emery L.I.
        • Green H.
        • Doherty D.A.
        • Hickey M.
        Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history.
        Menopause. 2014; 21: 267-274
        • Studdert D.M.
        Can liability rules keep pace with best practice? The case of multidisciplinary cancer care.
        Med. J. Aust. 2008; 188: 380-381